血浆白介素33水平与原发性肝癌及热消融治疗的相关性分析

肝脏 ›› 2023, Vol. 28 ›› Issue (6): 665-667.

血浆白介素33水平与原发性肝癌及热消融治疗的相关性分析

郭丹丹, 覃岭, 高文峰, 袁春旺, 张英华, 张永宏

100069 首都医科大学附属北京佑安医院(郭丹丹,高文峰,袁春旺,张英华,张永宏),肝病与肿瘤介入治疗中心教育处(覃岭)

收稿日期:2022-12-08 出版日期:2023-06-30 发布日期:2023-08-30
通讯作者: 张永宏,Email:zhangyh@ccmu.edu.cn
基金资助:
北京市自然科学基金重点项目(7191004) ;北京市科学技术委员会 (Z171 100001017078) ;2021年度北京佑安医院中青年人才孵育项目(YNKTQN2021014)

Correlation between the plasma levels of interleukin-33 and hepatocellular carcinoma, thermal ablation therapy

GUO Dan-dan¹, QIN Ling², GAO Weng-feng¹, YUAN Chun-wang¹, ZHANG Ying-hua¹, ZHANG Yong-hong¹

1. Interventional Therapy Center for Oncology, Beijing You’an Hospital, Capital Medical University, Beijing 100069, China;
2. Education Section, Beijing You’an Hospital, Capital Medical University, Beijing 100069, China

Received:2022-12-08 Online:2023-06-30 Published:2023-08-30
Contact: ZHANG Yong-hong,Email:zhangyh@ccmu.edu.cn

摘要/Abstract

摘要： 目的探讨血浆白介素33 (interleukin-33, IL-33)水平与原发性肝癌 (hepatocellular carcinoma, HCC) 及热消融治疗的相关性。方法选择2018年1月至2020年12月北京佑安医院收治的HCC患者30例,肝硬化患者25例和健康对照10例。采用酶联免疫吸附测定法 (enzyme linked immunosorbent assay, ELISA) 检测血浆IL-33水平。同时检测HCC中22例完全消融治疗患者术后1周、术后4周血浆IL-33水平。比较HCC组术前、肝硬化组和健康对照组血浆IL-33水平,以及HCC中完全消融治疗患者术前、术后1周和术后4周血浆IL-33水平。结果 HCC组、肝硬化组和健康对照组3组比较,HCC组术前血浆IL-33水平高于健康对照组[19.08 (12.02,31.91) pg/mL比(9.62+2.65)pg/mL],差异有统计学意义 (P=0.001);肝硬化组为3.05(9.87,17.56)pg/mL,LC组与HCC组和健康对照组相比,差异均无统计学意义(P>0.05)。中晚期HCC患者血浆IL-33水平高于早期患者[27.69 (16.06,34.90) pg/mL比17.18 (11.16,25.85) pg/mL],差异有统计学意义 (Z=2.031, P=0.043)。治疗效果达到完全消融治疗患者术后4周IL-33水平明显低于术前、术后1周分别为12.02 (9.23, 12.89) pg/mL、14.17 (11.16, 22.81) pg/mL、15.46 (13.74, 18.05) pg/mL,差异均有统计学意义(均P<0.05)。结论 IL-33表达失衡可能是HCC发生发展的重要机制之一;消融治疗可以纠正体内IL-33水平,促进IL-33恢复正常。

关键词: 原发性肝癌, 热消融治疗, IL-33

Abstract: Objective To investigate the correlation between the plasma levels of interleukin-33 (IL-33) and hepatocellular carcinoma (HCC), thermal ablation therapy. Methods A total of 30 HCC patients, 25 patients with liver cirrhosis patients and 10 healthy adults admitted to our hospital from January 2018 to December 2020 were enrolled. The plasma IL-33 levels were detected by enzyme-linked immunosorbent assay (ELISA). The plasma IL-33 levels were detected in 22 patients treated with complete ablation in HCC at 1 week postoperatively and 4 weeks postoperatively. The plasma IL-33 levels in HCC group before therapy, LC group and healthy control group were compared, and the dynamic changes of plasma IL-33 levels in HCC patients treated with complete ablation before ablation, week 1 and week 4 after ablation were analyzed. Results Compared with the HCC group, LC group and the healthy control group, the preoperative plasma IL-33 level in HCC group was significantly higher than that in healthy control group [19.08 (12.02-31.91) pg/mL vs (9.62+2.65) pg/mL], the difference was statistically significant (P=0.001). There was no significant difference between HCC group and LC group, between LC group and healthy control group (P＞0.05). The plasma IL-33 level in patients with middle and advanced stage (Barcelona clinic liver cancer, BCLC-B/C) was higher than that in patients with early stage (BCLC-0/A) [27.69 (16.06-34.90) pg/ml vs 17.18 (11.16-25.85) pg/mL], the difference was statistically significant (Z=2.031, P=0.043). The level of IL-33 at week 4 after complete ablation was significantly lower than that before treatment and 1 week after the operation [12.02 (9.23, 12.89) pg/mL vs 14.17 (11.16, 22.81) pg/mL, 15.46 (13.74, 18.05) pg/mL], with statistical significant (P=0.029, P<0.001). Conclusion Imbalance of IL-33 expression may be one of the important mechanisms in the development of HCC. Ablation therapy can change IL-33 levels and promote the return of IL-33 to normal.

Key words: Hepatocellular carcinoma, Thermal ablation therapy, Interleukin-33

郭丹丹, 覃岭, 高文峰, 袁春旺, 张英华, 张永宏. 血浆白介素33水平与原发性肝癌及热消融治疗的相关性分析[J]. 肝脏, 2023, 28(6): 665-667.

GUO Dan-dan, QIN Ling, GAO Weng-feng, YUAN Chun-wang, ZHANG Ying-hua, ZHANG Yong-hong. Correlation between the plasma levels of interleukin-33 and hepatocellular carcinoma, thermal ablation therapy[J]. Chinese Hepatolgy, 2023, 28(6): 665-667.

参考文献

[1] Huang N, Cui X, Li W, et al. IL-33/ST2 promotes the malignant progression of gastric cancer via the MAPK pathway. Mol Med Rep, 2021 May;23(5):361.
[2] Yamagishi R, Kamachi F, Nakamura M, et al. Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma. Sci Immunol, 2022, 7(72): eabl7209.
[3] Askoura M, Abbas HA, Al Sadoun H, et al. Elevated levels of IL-33, IL-17 and IL-25 indicate the progression from chronicity to hepatocellular carcinoma in hepatitis C virus patients. Pathogens, 2022, 11(1):57.
[4] Huang KW, Jayant K, Lee PH, et al. Positive immuno-modulation following radiofrequency assisted liver resection in hepatocellular carcinoma. J Clin Med, 2019, 8(3): 385.
[5] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022 年版). 中华肝脏病杂志, 2022, 30(4): 367-388.
[6] Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 1999, 19(3):329-338.
[7] 中华医学会肝病学分会. 肝硬化诊治指南. 中华肝脏病杂志, 2019, 27(1): 846-865.
[8] Cayrol C, Girard JP. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. Immunol Rev. 2018, 281(1):154-168.
[9] Molofsky AB, Savage AK, Locksley RM. Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity, 2015, 42(6):1005-1019.
[10] Chang CP, Hu MH, Hsiao YP, et al. ST2 Signaling in the Tumor Microenvironment. Adv Exp Med Biol. 2020, 1240:83-93.
[11] Zhang P, Liu XK, Chu Z,et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res, 2012, 40(5):1654-1661.
[12] Jin Z, Lei L, Lin D, et al. IL-33 Released in the liver inhiibits tumor growth via promotion of CD4⁺ and CD8⁺T cell responses in hepatocellular carcinoma. J Immunol, 2018, 201(12): 3770-3779.
[13] Brunner SM, Rubner C, Kesselring R, et al. Tumor- infiltrating, interleukin-33 producing effector-memory CD8⁺ T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology, 2015, 61(6):1957-1967.
[14] Zhao R, Yu Z, Li M, et al. Interleukin-33/ST2 signaling promotes hepatocellular carcinoma cell stemness expansion through activating c-Jun N-terminal kinase pathway. Am J Med Sci. 2019, 358(4): 279-288.
[15] Berjis D, Kassis V, Ranglack A, et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol, 2013, 6(3):311-318.
[16] Yang Y, Wang JB, Li YM, et al. Role if IL-33 expression in oncogenesis and development of human hepatocellular carcinoma. Oncol Lett, 2016,12(1):429-436.
[17] Chen X, Ren Z, Yin S, et al. The local liver ablation with pulsed electric field stimulate systemic immune reaction against hepatocellular carcinoma (HCC) with time-dependent cytokine profile. Cytokine, 2017, 93:44-50.
[18] Zhao J, Li Q, Muktiali M, et al. Effect of microwave ablation treatment of hepatic malignancies on serum cytokine levels. BMC Cancer. 2020, 20(1): 812.
[19] Zhang H, Hou X, Cai H, et al. Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma. Minim Invasive Ther Allied Technol, 2017, 26(4):207-211.